MEDIA RELEASE PR35419
NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
NEW YORK, July 16 /PRNewswire-AsiaNet/ --
NeoStem, Inc. (NYSE Amex: NBS), which is pioneering the pre-disease
collection, processing and long-term storage of adult stem cells for future
medical need, announced today it has entered into an advisory consulting
agreement with Dr. Cai Jianqian, (Mrs Mao) of the Shandong Provincial
Association of Chinese Medicine, to assist the company with its expansion
into China and facilitate collaborations with prestigious hospitals in the
Peoples Republic of China.
Ms. Cai Jianqian, a graduate of Shandong University of Traditional
Chinese Medicine, has held the positions of Chief of the Administration of
Chinese Medicine of Shandong Province, standing Council Member of the China
Association of Chinese Medicine, Chairman of the Medicated Diet Association,
Member of the lecturer team on Chinese acupuncture and moxibustion, and
Corporate Representative of the Shandong Provincial Association of Chinese
Medicine.
Ms. Cai held senior positions at China's State Drug Administration and
its predecessor for many years, was responsible for creating the development
strategies and long-term and middle-term planning of the industry, and is
considered by many to be instrumental in the continual improvement of the
standards of medicine, education and research in the Chinese medicine
industry. She was appointed in 1983 to head Chinese Medical Affairs of
Shandong province, and during her tenure the number of Chinese medicine
hospitals in Shandong province increased from eight to 150. In addition to
being responsible for having established the Shandong Academy of Chinese
Medicine and the Shandong Academy of Acupuncture and Moxibustion, she has
been consistently praised by the Ministry of Health and the State
Administration of Traditional Chinese Medicine for having made Shandong
province one of the top ranked provinces in the PRC for Chinese medicine
advancement.
A Council member of the American General Medical Association as well as a
member of the editorial board of The Journal of American General Medicine,
Ms. Cai is responsible for having established The Chinese Traditional
Medicine Center in Chicago, two Chinese medicine hospitals in South Africa,
twelve Chinese medicine outpatient clinics in Switzerland and the Chinese
medicine rehabilitation centers in Poland and Russia. She has been
extensively published in her field and is well regarded for her work in the
research and development of new drugs, including the clinical study of
complex diseases and acute illness, including cancer. She has been awarded an
International MD and is certified by the International Open Traditional
Medicine University & Institute of Medical Science of the United Nations, and
the International Association of Traditional Medicine in Colombo in 1999.
Robin Smith, M.D., MBA, NeoStem's Chief Executive Officer, said, "We are
extremely pleased to welcome Ms. Cai to the NeoStem team and are confident
that her extraordinary intellectual, administrative and political experience
will guide the company as it expands abroad". Ms. Cai stated, "I'm delighted
to be affiliated with NeoStem Inc. This Company's vision for collaborative
medical innovation in the United States and China, especially in the field of
stem cell research and applications using VSELs, opens enormous potential for
both nations."
About NeoStem, Inc.
NeoStem is developing a network of adult stem cell collection centers
that are focused on enabling people to donate and store their own
(autologous) stem cells when they are young and healthy for their personal
use in times of future medical need. The Company has also entered into
research and development through the acquisition of a worldwide exclusive
license to technology to identify and isolate VSELs (very small
embryonic-like stem cells), which have been shown to have several physical
characteristics that are generally found in embryonic stem cells and is
pursuing other technologies to advance its position in the field of stem cell
tissue regeneration.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. The Company's
actual results could differ materially from those anticipated in these
forward-looking statements as a result of various factors. Factors that could
cause future results to materially differ from the recent results or those
projected in forward-looking statements include the "Risk Factors" described
in the Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2008 and the Company's other periodic filings with the
Securities and Exchange Commission. The Company's further development is
highly dependent on future medical and research developments and market
acceptance, which is outside its control.
CONTACT:
NeoStem, Inc.
Robin Smith, Chief Executive Officer
T: 212-584-4180
E: rsmith@neostem.com
SOURCE: NeoStem, Inc.
CONTACT: Robin Smith, Chief Executive Officer of NeoStem, Inc.,
+1-212-584-4180
rsmith@neostem.com
(NBS)
NEWS 
